BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

This publication has 31 references indexed in Scilit:

• Prostate Cancer
  JAMA, 2025
• Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
  European Urology Oncology, 2024
• Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
  Annals of Oncology, 2024
• Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
  European Urology Oncology, 2023
• Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
  Annals of Oncology, 2023
• Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
  European Journal of Cancer, 2023
• The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer
  Clinical Genitourinary Cancer, 2022
• HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
  Annals of Oncology, 2020
• Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
  The Prostate, 2018
• DNA Repair in Prostate Cancer: Biology and Clinical Implications
  European Urology, 2017